Palvella Therapeutics, Inc.
PVLA
$156.13
-$0.42-0.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 116.17% | 45.40% | 129.46% | 94.10% | 181.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 131.41% | 88.73% | 158.91% | 101.05% | 218.09% |
| Operating Income | -131.41% | -88.73% | -158.91% | -101.05% | -218.09% |
| Income Before Tax | -130.92% | -92.63% | -221.79% | -67.45% | -127.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -130.92% | -92.63% | -221.79% | -67.45% | -127.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.92% | -92.63% | -221.79% | -67.45% | -127.01% |
| EBIT | -131.41% | -88.73% | -158.91% | -101.05% | -218.09% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -77.78% | -62.12% | -14.21% | 73.95% | 65.26% |
| Normalized Basic EPS | -77.76% | -62.13% | 31.53% | 70.76% | 63.64% |
| EPS Diluted | -77.78% | -62.12% | -14.21% | 73.95% | 65.26% |
| Normalized Diluted EPS | -77.76% | -62.13% | 31.53% | 70.76% | 63.64% |
| Average Basic Shares Outstanding | 29.89% | 18.81% | 230.45% | 525.03% | 524.38% |
| Average Diluted Shares Outstanding | 29.89% | 18.81% | 230.45% | 525.03% | 524.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |